Mild Cognitive Impairment Staging Yields Genetic Susceptibility, Biomarker, and Neuroimaging Differences

Overview of attention for article published in Frontiers in Aging Neuroscience, June 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (88th percentile)
High Attention Score compared to outputs of the same age and source (89th percentile)

So far, Altmetric has seen 19 X posts from 15 X users, with an upper bound of 108,971 followers.

RT @VUMCneurology: *Clinician-derived mild cognitive impairment severity stages yielded differences in APOE-ε4 status, CSF biomarkers, neur…

*Clinician-derived mild cognitive impairment severity stages yielded differences in APOE-ε4 status, CSF biomarkers, neuroimaging outcomes, & neuropsychological trajectory. @EMoore1225 @acostalmd @schrag_matthew @timothyjhohman @VanderbiltAlz @FrontNeur

RT @VUMCneurology: Clinician-derived mild cognitive impairment severity stages yielded differences in APOE-ε4 status, CSF biomarkers, neuro…

RT @VUMCneurology: Clinician-derived mild cognitive impairment severity stages yielded differences in APOE-ε4 status, CSF biomarkers, neuro…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 15 additional X posts.